Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Fischer, K; Cramer, P; Busch, R; Böttcher, S; Bahlo, J; Schubert, J; Pflüger, KH; Schott, S; Goede, V; Isfort, S; von Tresckow, J; Fink, AM; Bühler, A; Winkler, D; Kreuzer, KA; Staib, P; Ritgen, M; Kneba, M; Döhner, H; Eichhorst, BF; Hallek, M; Stilgenbauer, S; Wendtner, CM 
Titel:
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. 
Abstract:
We investigated the safety and efficacy of bendamustine and rituximab (BR) in previously untreated patients with chronic lymphocytic leukemia (CLL).In all, 117 patients, age 34 to 78 years, 46.2% of patients at Binet stage C, and 25.6% of patients age 70 years or older received BR chemoimmunotherapy for first-line treatment of CLL. Bendamustine was administered at a dose of 90 mg/m(2) on days 1 and 2 combined with 375 mg/m(2) rituximab on day 0 of the first course and 500 mg/m(2) on day 1 during...    »
 
Zeitschriftentitel:
J Clin Oncol 
Jahr:
2012 
Band / Volume:
30 
Heft / Issue:
26 
Seitenangaben Beitrag:
3209-16 
Sprache:
eng 
Print-ISSN:
0732-183X 
TUM Einrichtung:
r Medizinische Statistik und Epidemiologie